Navigation Links
Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
Date:10/27/2008

KOBE, Japan, Oct. 27 /PRNewswire/ -- Carna Biosciences, Inc. ("Carna") announced on October 27, 2008, the signing of a Distribution Agreement with Shanghai Universal Biotech Company ("SUBC"). Under the terms of this Agreement, SUBC will become the exclusive distributor of Carna's Protein Kinases within China.

With China's emergence as a strong market opportunity, particularly in the life sciences, major biopharmaceutical companies have now established research and production facilities in Shanghai and other regions of China. These facilities seek and require goods to support their internal drug discovery programs. Carna is an established global provider of protein kinases used in the discovery and development of the important class of drugs known as kinase inhibitors. The Agreement with SUBC makes these products readily available to Chinese researchers via SUBC's strong distribution channels.

In addition to major biopharmaceutical presence, tax incentives provided by the Chinese government have provided a fertile environment for the establishment of bio-venture companies and CRO. The Agreement between Carna and SUBC, with its offices in the major cities of Shanghai and Beijing, is anticipated to lead to significantly increased sales opportunities for Carna and further establish its reputation as a global provider of protein kinases.

About Carna

Carna Biosciences, Inc. (http://www.carnabio.com/english/), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, and providing drug discovery services to pharmaceutical companies using proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development. The products and services provided by Carna include kinase proteins, assay development services, kinase profiling and screening services, and crystallography products and services.

About SUBC

Shanghai Universal Biotech Company(http://www.univ-bio.com), founded in December 2004, is a Chinese distributor of biological reagents and experimental installations. The company provides antibody and reagent products as an agent of biological companies at home and abroad.
Contact:

Tomohisa Yamazaki, Manager

Corporate Planning

Carna Biosciences, Inc.

Phone: +81-78-302-7039

Fax: +81-78-302-6665

E-mail: ir-team@carnabio.com

URL: http://www.carnabio.com/english/


'/>"/>
SOURCE Carna Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
2. Isis Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
3. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
5. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
6. Pressure BioSciences, Inc. Provides Corporate Update
7. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
8. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
9. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... -- Scientists propose in Nature blocking a ... and maybe other lysosomal storage diseases as a possible ... therapies. An international research team led by ... included investigators from the University of Lübeck in ... The study was conducted in mouse models of lysosomal ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or ... neurodegenerative diseases, today announced it has issued a scientific white paper entitled “Results ... a series of commentaries from ProMIS’s scientific team offering insight into the Company’s ...
Breaking Biology Technology:
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):